Lupin gains as its arm signs definitive agreement to acquire VISUfarma B.V.
Lupin is currently trading at Rs. 1935.00, up by 14.25 points or 0.74% from its previous closing of Rs. 1920.75 on the BSE.
The scrip opened at Rs. 1922.65 and has touched a high and low of Rs. 1938.95 and Rs. 1922.10 respectively. So far 1964 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2054.30 and Rs. 1912.90 respectively. The current market cap of the company is Rs. 88072.05 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 46.81% and 6.28% respectively.
Lupin’s wholly owned subsidiary -- Nanomi B.V. (Nanomi) has signed a definitive agreement for the acquisition of VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare specialist investor GHO Capital Partners LLP (GHO). The acquisition of VISUfarma, with its broad portfolio of innovative eye health products and established commercial infrastructure, aligns with Lupin’s strategy to expand its European business and footprint and to advance the company’s global specialty franchise.
By integrating VISUfarma’s established commercial operations, Lupin will tap into the attractive ophthalmology market, which is experiencing significant global growth driven by an aging global population, the increasing incidence of diabetes-related eye complications, and growing awareness of preventive care.
With the integration of VISUfarma, Lupin will offer a complete portfolio of products in the areas of dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and highly focused nutraceuticals prescribed by ophthalmologists. Lupin will finance the acquisition with existing cash on balance sheet. The acquisition is expected to be accretive to Lupin’s growth and margin profile. The transaction is projected to close by the end of 2025, subject to certain closing conditions.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
